{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:12:31Z","timestamp":1785341551489,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,5,18]],"date-time":"2005-05-18T00:00:00Z","timestamp":1116374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,5,18]],"date-time":"2005-05-18T00:00:00Z","timestamp":1116374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Widespread use of fluoroquinolones has resulted in emergence of <jats:italic>Salmonella typhi<\/jats:italic> strains with decreased susceptibility to fluoroquinolones. These strains are identifiable by their nalidixic acid-resistance. We studied the impact of infection with nalidixic acid-resistant <jats:italic>S. typhi<\/jats:italic> (NARST) on clinical outcomes in patients with bacteriologically-confirmed typhoid fever.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Clinical and laboratory features, fever clearance time and complications were prospectively studied in patients with blood culture-proven typhoid fever, treated at a tertiary care hospital in north India, during the period from November 2001 to October 2003. Susceptibility to amoxycillin, co-trimoxazole, chloramphenicol, ciprofloxacin and ceftriaxone were tested by disc diffusion method. Minimum inhibitory concentrations (MIC) of ciprofloxacin and ceftriaxone were determined by E-test method.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>During a two-year period, 60 patients (age [mean \u00b1 SD]: 15 \u00b1 9 years; males: 40 [67%]) were studied. All isolates were sensitive to ciprofloxacin and ceftriaxone by disc diffusion and MIC breakpoints. However, 11 patients had clinical failure of fluoroquinolone therapy. Infections with NARST isolates (47 [78%]) were significantly associated with longer duration of fever at presentation (median [IQR] 10 [7-15] vs. 4 [3-6] days; P = 0.000), higher frequency of hepatomegaly (57% vs. 15%; P = 0.021), higher levels of aspartate aminotransferase (121 [66\u2013235] vs. 73 [44\u2013119] IU\/L; P = 0.033), and increased MIC of ciprofloxacin (0.37 \u00b1 0.21 vs. 0.17 \u00b1 0.14 \u03bcg\/mL; P = 0.005), as compared to infections with nalidixic acid-susceptible isolates. All 11 patients with complications were infected with NARST isolates. Total duration of illness was significantly longer in patients who developed complications than in patients who did not (22 [14.8\u201332] vs. 12 [9.3\u201320.3] days; P = 0.011). Duration of prior antibiotic intake had a strong positive correlation with the duration of fever at presentation (r = 0.61; P = 0.000) as well as the total duration of illness (r = 0.53; P = 0.000).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Typhoid fever caused by NARST infection is associated with poor clinical outcomes, probably due to delay in initiating appropriate antibiotic therapy. Fluoroquinolone breakpoints for <jats:italic>S. typhi<\/jats:italic> need to be redefined and fluoroquinolones should no longer be used as first-line therapy, if the prevalence of NARST is high.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1471-2334-5-37","type":"journal-article","created":{"date-parts":[[2005,5,18]],"date-time":"2005-05-18T18:14:05Z","timestamp":1116440045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi"],"prefix":"10.1186","volume":"5","author":[{"given":"Tamilarasu","family":"Kadhiravan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveet","family":"Wig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Kapil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SK","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Renuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,5,18]]},"reference":[{"key":"185_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S0140-6736(98)09001-1","volume":"354","author":"A Sinha","year":"1999","unstructured":"Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, Rao M, Naficy A, Clemens JD, Bhan MK: Typhoid fever in children aged less than 5 years. Lancet. 1999, 354: 734-737. 10.1016\/S0140-6736(98)09001-1.","journal-title":"Lancet"},{"key":"185_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archinte.158.6.633","volume":"158","author":"JH Mermin","year":"1998","unstructured":"Mermin JH, Townes JM, Gerber M, Dolan N, Mintz ED, Tauxe RV: Typhoid fever in the United States, 1985\u20131994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med. 1998, 158: 633-638. 10.1001\/archinte.158.6.633.","journal-title":"Arch Intern Med"},{"key":"185_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1365-3156.1999.43374.x","volume":"4","author":"ET van den Bergh","year":"1999","unstructured":"van den Bergh ET, Gasem MH, Keuter M, Dolmans MV: Outcome in three groups of patients with typhoid fever in Indonesia between 1948 and 1990. Trop Med Int Health. 1999, 4: 211-215. 10.1046\/j.1365-3156.1999.43374.x.","journal-title":"Trop Med Int Health"},{"issue":"Suppl 1","key":"185_CR4","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1093\/clinids\/24.Supplement_1.S106","volume":"24","author":"B Rowe","year":"1997","unstructured":"Rowe B, Ward LR, Threlfall EJ: Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis. 1997, 24 (Suppl 1): S106-S109.","journal-title":"Clin Infect Dis"},{"key":"185_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3201\/eid0703.017315","volume":"7","author":"EJ Threlfall","year":"2001","unstructured":"Threlfall EJ, Ward LR: Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom. Emerg Infect Dis. 2001, 7: 448-450.","journal-title":"Emerg Infect Dis"},{"key":"185_CR6","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1001\/jama.283.20.2668","volume":"283","author":"ML Ackers","year":"2000","unstructured":"Ackers ML, Puhr ND, Tauxe RV, Mintz ED: Laboratory-based surveillance of Salmonella serotype typhi infections in the United States \u2013 Anti-microbial resistance on the rise. JAMA. 2000, 283: 2668-2673. 10.1001\/jama.283.20.2668.","journal-title":"JAMA"},{"key":"185_CR7","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMra020201","volume":"347","author":"CM Parry","year":"2002","unstructured":"Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ: Typhoid fever. N Engl J Med. 2002, 347: 1770-1782. 10.1056\/NEJMra020201.","journal-title":"N Engl J Med"},{"key":"185_CR8","first-page":"88","volume":"12","author":"KG Bhat","year":"1999","unstructured":"Bhat KG, Suresh K: Ciprofloxacin-resistant Salmonella typhi. Natl Med J India. 1999, 12: 88-","journal-title":"Natl Med J India"},{"key":"185_CR9","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(99)01001-6","volume":"353","author":"EJ Threlfall","year":"1999","unstructured":"Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S: Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet. 1999, 353: 1590-1591. 10.1016\/S0140-6736(99)01001-6.","journal-title":"Lancet"},{"key":"185_CR10","first-page":"210","volume":"113","author":"P Dutta","year":"2001","unstructured":"Dutta P, Mitra U, Dutta S, De A, Chatterjee MK, Bhattacharya SK: Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children. Indian J Med Res. 2001, 113: 210-213.","journal-title":"Indian J Med Res"},{"key":"185_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1086\/516128","volume":"25","author":"J Wain","year":"1997","unstructured":"Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ, Diep TS, Day NP, Solomon T, White NJ, Piddock LJ, Parry CM: Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis. 1997, 25: 1404-1410.","journal-title":"Clin Infect Dis"},{"key":"185_CR12","volume-title":"Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6","author":"National Committee for Clinical Laboratory Standards","year":"2000","unstructured":"National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. 2000, Wayne, PA: NCCLS, 7","edition":"7"},{"key":"185_CR13","first-page":"49","volume":"115","author":"A Kapil","year":"2002","unstructured":"Kapil A, Renuka , Das B: Nalidixic acid susceptibility test to screen ciprofloxacin resistance in Salmonella typhi. Indian J Med Res. 2002, 115: 49-54.","journal-title":"Indian J Med Res"},{"key":"185_CR14","first-page":"88","volume":"12","author":"C Rodrigues","year":"1999","unstructured":"Rodrigues C, Mehta A, Joshi VR: Nalidixic acid-resistant Salmonella typhi in Mumbai. Natl Med J India. 1999, 12: 88-","journal-title":"Natl Med J India"},{"key":"185_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/1076629041310028","volume":"10","author":"K Renuka","year":"2004","unstructured":"Renuka K, Kapil A, Kabra SK, Wig N, Das BK, Prasad VV, Chaudhry R, Seth P: Reduced susceptibility to ciprofloxacin and gyr-a gene mutation in North Indian strains of Salmonella enterica serotype Typhi and serotype Paratyphi A. Microb Drug Resist. 2004, 10: 146-153. 10.1089\/1076629041310028.","journal-title":"Microb Drug Resist"},{"key":"185_CR16","first-page":"247","volume":"103","author":"MV Jesudason","year":"1996","unstructured":"Jesudason MV, Malathy B, John TJ: Trend of increasing levels of minimum inhibitory concentration of ciprofloxacin to Salmonella typhi. Indian J Med Res. 1996, 103: 247-249.","journal-title":"Indian J Med Res"},{"key":"185_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1086\/375602","volume":"37","author":"JA Crump","year":"2003","unstructured":"Crump JA, Barrett TJ, Nelson JT, Angulo FJ: Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis. 2003, 37: 75-81. 10.1086\/375602.","journal-title":"Clin Infect Dis"},{"key":"185_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1128\/AAC.47.2.827-829.2003","volume":"47","author":"FM Aarestrup","year":"2003","unstructured":"Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ: Is it time to change fluoroquinolone breakpoints for Salmonella spp.?. Antimicrob Agents chemother. 2003, 47: 827-829. 10.1128\/AAC.47.2.827-829.2003.","journal-title":"Antimicrob Agents chemother"},{"key":"185_CR19","volume-title":"Performance standards for antimicrobial susceptibility testing: thirteenth informational supplement. NCCLS document M100-S13(M7)","author":"National Committee for Clinical Laboratory Standards","year":"2003","unstructured":"National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing: thirteenth informational supplement. NCCLS document M100-S13(M7). 2003, Wayne, PA: NCCLS"},{"key":"185_CR20","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1128\/JCM.37.11.3572-3577.1999","volume":"37","author":"A Hakanen","year":"1999","unstructured":"Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P: Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol. 1999, 37: 3572-3577.","journal-title":"J Clin Microbiol"},{"key":"185_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2334-4-36","volume":"4","author":"R Slinger","year":"2004","unstructured":"Slinger R, Desjardins M, McCarthy AE, Ramotar K, Jessamine P, Guibord C, Toye B: Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis. 2004, 4: 36-10.1186\/1471-2334-4-36.","journal-title":"BMC Infect Dis"},{"key":"185_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jac\/33.1.103","volume":"33","author":"C Catchpole","year":"1994","unstructured":"Catchpole C, Andrews JM, Woodcock J, Wise R: The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother. 1994, 33: 103-110.","journal-title":"J Antimicrob Chemother"},{"key":"185_CR23","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1345\/aph.1C419","volume":"37","author":"JJ Schentag","year":"2003","unstructured":"Schentag JJ, Meagher AK, Forrest A: Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother. 2003, 37: 1478-1488. 10.1345\/aph.1C419.","journal-title":"Ann Pharmacother"},{"key":"185_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/004947550003000404","volume":"30","author":"SK Kabra","year":"2000","unstructured":"Kabra SK, Madhulika , Talati A, Soni N, Patel S, Modi RR: Multidrug-resistant typhoid fever. Trop Doct. 2000, 30: 195-197.","journal-title":"Trop Doct"},{"key":"185_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/adc.75.3.214","volume":"75","author":"ZA Bhutta","year":"1996","unstructured":"Bhutta ZA: Impact of age and drug resistance on mortality in typhoid fever. Arch Dis Child. 1996, 75: 214-217.","journal-title":"Arch Dis Child"},{"key":"185_CR26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1742-1241.1997.tb09617.x","volume":"51","author":"H Alsoub","year":"1997","unstructured":"Alsoub H, Uwaydah AK, Matar I, Zebeib M, Elhag KM: A clinical comparison of typhoid fever caused by susceptible and multidrug-resistant strains of Salmonella typhi. Br J Clin Pract. 1997, 51: 8-10.","journal-title":"Br J Clin Pract"},{"key":"185_CR27","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1128\/JCM.36.6.1683-1687.1998","volume":"36","author":"J Wain","year":"1998","unstructured":"Wain J, Diep TS, Ho VA, Walsh AM, Nguyen TT, Parry CM, White NJ: Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol. 1998, 36: 1683-1687.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1471-2334-5-37\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:41:30Z","timestamp":1728304890000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-5-37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,12]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-5-37","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,18]]},"assertion":[{"value":"23 October 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"37"}}